Search

Your search keyword '"Pusceddu, Sara"' showing total 371 results
Start Over Author "Pusceddu, Sara" Publication Year Range Last 10 years
371 results on '"Pusceddu, Sara"'

1. The LUTADOSE trial: tumour dosimetry after the first administration predicts progression free survival in gastro-entero-pancreatic neuroendocrine tumours (GEP NETs) patients treated with [177Lu]Lu-DOTATATE

Author

Maccauro, Marco, Cuomo, Mariarosaria, Bauckneht, Matteo, Bagnalasta, Matteo, Mazzaglia, Stefania, Scalorbi, Federica, Argiroffi, Giovanni, Kirienko, Margarita, Lorenzoni, Alice, Aliberti, Gianluca, Pusceddu, Sara, Giuseppina, Calareso, Matteo, Garanzini Enrico, Seregni, Ettore, and Chiesa, Carlo

Published
2024
Full Text
View/download PDF

5. Characterization of two transcriptomic subtypes of marker-null large cell carcinoma of the lung suggests different origin and potential new therapeutic perspectives

Author

Simbolo, Michele, Centonze, Giovanni, Gkountakos, Anastasios, Monti, Valentina, Maisonneuve, Patrick, Golovco, Stela, Sabella, Giovanna, Del Gobbo, Alessandro, Gobbo, Stefano, Ferrero, Stefano, Fabbri, Alessandra, Pardo, Carlotta, Garzone, Giovanna, Prinzi, Natalie, Pusceddu, Sara, Testi, Adele, Rolli, Luigi, Mangogna, Alessandro, Bercich, Luisa, Benvenuti, Mauro Roberto, Bria, Emilio, Pilotto, Sara, Berruti, Alfredo, Pastorino, Ugo, Capella, Carlo, Infante, Maurizio, Milella, Michele, Scarpa, Aldo, and Milione, Massimo

Published
2024
Full Text
View/download PDF

6. Epidemiology of gastroenteropancreatic neuroendocrine neoplasms: a review and protocol presentation for bridging tumor registry data with the Italian association for neuroendocrine tumors (Itanet) national database

Author

Panzuto, Francesco, Partelli, Stefano, Campana, Davide, de Braud, Filippo, Spada, Francesca, Cives, Mauro, Tafuto, Salvatore, Bertuzzi, Alexia, Gelsomino, Fabio, Bergamo, Francesca, Marcucci, Stefano, Mastrangelo, Laura, Massironi, Sara, Appetecchia, Marialuisa, Filice, Angelina, Badalamenti, Giuseppe, Bartolomei, Mirco, Amoroso, Vito, Landoni, Luca, Rodriquenz, Maria Grazia, Valente, Monica, Colao, Annamaria, Isidori, Andrea, Fanciulli, Giuseppe, Bollina, Roberto, Ciola, Michele, Butturini, Giovanni, Marconcini, Riccardo, Arvat, Emanuela, Cinieri, Saverio, Berardi, Rossana, Baldari, Sergio, Riccardi, Ferdinando, Spoto, Chiara, Giuffrida, Dario, Gattuso, Domenico, Ferone, Diego, Rinzivillo, Maria, Bertani, Emilio, Versari, Annibale, Zerbi, Alessandro, Lamberti, Giuseppe, Lauricella, Eleonora, Pusceddu, Sara, Fazio, Nicola, Dell’Unto, Elisabetta, Marini, Marco, and Falconi, Massimo

Published
2024
Full Text
View/download PDF

7. Sunitinib for the treatment of patients with advanced pheochromocytomas or paragangliomas: The phase 2 non-randomized SUTNET clinical trial

Author

Nasca, Vincenzo, Prinzi, Natalie, Coppa, Jorgelina, Prisciandaro, Michele, Oldani, Simone, Ghelardi, Filippo, Conca, Elena, Capone, Iolanda, Busico, Adele, Perrone, Federica, Tamborini, Elena, Sabella, Giovanna, Greco, Giorgio, Greco, Francesca Gabriella, Tafuto, Salvatore, Procopio, Giuseppe, Morano, Federica, Niger, Monica, Maccauro, Marco, Milione, Massimo, de Braud, Filippo, Pietrantonio, Filippo, and Pusceddu, Sara

Published
2024
Full Text
View/download PDF

8. Adverse skeletal related events in patients with bone-metastatic pheochromocytoma/paraganglioma

Author

Laganà, Marta, Habra, Mouhammed Amir, Remde, Hanna, Almeida, Madson Q., Cosentini, Deborah, Pusceddu, Sara, Grana, Chiara Maria, Corssmit, Eleonora P.M., Bongiovanni, Alberto, De Filpo, Giuseppina, Lim, Eugenie S., Zamparini, Manuel, Grisanti, Salvatore, Deutschbein, Timo, Fassnacht, Martin, Fagundes, Gustavo F.C., Pereira, Maria Adelaide A., Oldani, Simone, Rota, Simone, Prinzi, Natalie, Jimenez, Camilo, and Berruti, Alfredo

Published
2024
Full Text
View/download PDF

9. A randomized phase II trial of Captem or Folfiri as second-line therapy in neuroendocrine carcinomas

Author

Bongiovanni, Alberto, Liverani, Chiara, Foca, Flavia, Bergamo, Francesca, Leo, Silvana, Pusceddu, Sara, Gelsomino, Fabio, Brizzi, Maria Pia, Di Meglio, Giovanni, Spada, Francesca, Tamberi, Stefano, Lolli, Ivan, Cives, Mauro, Marconcini, Riccardo, Pucci, Francesca, Berardi, Rossana, Antonuzzo, Lorenzo, Badalamenti, Giuseppe, Santini, Daniele, Recine, Federica, Vanni, Silvia, Tebaldi, Michela, Severi, Stefano, Rudnas, Britt, Nanni, Oriana, Ranallo, Nicoletta, Crudi, Laura, Calabrò, Luana, and Ibrahim, Toni

Published
2024
Full Text
View/download PDF

10. Safety and antitumor activity of metformin plus lanreotide in patients with advanced gastro-intestinal or lung neuroendocrine tumors: the phase Ib trial MetNET2

Author

Pusceddu, Sara, Corti, Francesca, Prinzi, Natalie, Nichetti, Federico, Ljevar, Silva, Busico, Adele, Cascella, Tommaso, Leporati, Rita, Oldani, Simone, Pircher, Chiara Carlotta, Coppa, Jorgelina, Resi, Veronica, Milione, Massimo, Maccauro, Marco, Miceli, Rosalba, Tamborini, Elena, Perrone, Federica, Spreafico, Carlo, Niger, Monica, Morano, Federica, Pietrantonio, Filippo, Seregni, Ettore, Mariani, Luigi, Mazzaferro, Vincenzo, Di Liberti, Giorgia, Fucà, Giovanni, de Braud, Filippo, and Vernieri, Claudio

Published
2023
Full Text
View/download PDF

11. Assessing the safety and activity of cabozantinib combined with lanreotide in gastroenteropancreatic and thoracic neuroendocrine tumors: rationale and protocol of the phase II LOLA trial

Author

Corti, Francesca, Brizzi, Maria Pia, Amoroso, Vito, Giuffrida, Dario, Panzuto, Francesco, Campana, Davide, Prinzi, Natalie, Milione, Massimo, Cascella, Tommaso, Spreafico, Carlo, Randon, Giovanni, Oldani, Simone, Leporati, Rita, Scotto, Giulia, Pulice, Iolanda, Stocchetti, Benedetta Lombardi, Porcu, Luca, Coppa, Jorgelina, Di Bartolomeo, Maria, de Braud, Filippo, and Pusceddu, Sara

Published
2023
Full Text
View/download PDF

14. Management of the congenital solitary kidney: consensus recommendations of the Italian Society of Pediatric Nephrology

Author

La Scola, Claudio, Ammenti, Anita, Bertulli, Cristina, Bodria, Monica, Brugnara, Milena, Camilla, Roberta, Capone, Valentina, Casadio, Luca, Chimenz, Roberto, Conte, Maria L., Conversano, Ester, Corrado, Ciro, Guarino, Stefano, Luongo, Ilaria, Marsciani, Martino, Marzuillo, Pierluigi, Meneghesso, Davide, Pennesi, Marco, Pugliese, Fabrizio, Pusceddu, Sara, Ravaioli, Elisa, Taroni, Francesca, Vergine, Gianluca, Peruzzi, Licia, and Montini, Giovanni

Published
2022
Full Text
View/download PDF

15. The LUTADOSE trial: tumour dosimetry after the first administration predicts progression free survival in gastro-entero-pancreatic neuroendocrine tumours (GEP NETs) patients treated with [177Lu]Lu-DOTATATE.

Author

Maccauro, Marco, Cuomo, Mariarosaria, Bauckneht, Matteo, Bagnalasta, Matteo, Mazzaglia, Stefania, Scalorbi, Federica, Argiroffi, Giovanni, Kirienko, Margarita, Lorenzoni, Alice, Aliberti, Gianluca, Pusceddu, Sara, Giuseppina, Calareso, Matteo, Garanzini Enrico, Seregni, Ettore, and Chiesa, Carlo

Abstract

Purpose: In Peptide Receptor Radionuclide Therapy (PRRT) with [177Lu]Lu-DOTATATE of gastro-entero-pancreatic neuroendocrine tumours (GEP NETs) a question remains open about the potential benefits of personalised dosimetry. This observational prospective study examines the association of individualized dosimetry with progression free survival (PFS) in G1-G2 GEP NETs patients following the standard [177Lu]Lu-DOTATATE therapeutic regimen. Methods: The analysis was conducted on 42 patients administered 4 times, and on 165 lesions. Dosimetry was performed after the first and the forth cycle, with two SPECT/CT scans at day 1 and 7 after administration. Global mean Tumour absorbed Dose of each patient (GTD) was calculated after cycle 1 and 4 as the sum of lesion doses weighted by lesion mass, normalized by the global tumour mass. Cumulative GTD_TOT was calculated as the mean between cycle 1 (GTD_1) and 4 (GTD_4) multiplied by 4. Patients were followed-up for median 32.8 (range 18–45.5) months, through blood tests and contrast enhanced CT (ceCT). This study assessed the correlation between global tumour dose (GTD) and PFS longer or shorter than 24 months. After a ROC analysis, we stratified patients according to the best cut-off value for two additional statistical analyses. At last a multivariate analysis was carried out for PFS > / < 24 months. Results: The median follow-up interval was 33 months, ranging from 18 to 45.5 months. The median PFS was 42 months. The progression free survival rate at 20 months was 90.5%. GTD_1 and GTD_TOT were statistically associated with PFS > / < 24 m (p = 0.026 and p = 0.03 respectively). The stratification of patients on GTD_1 lower or higher than the best cut-off value at 10.6 Gy provided significantly different median PFS of 21 months versus non reached, i.e. longer than 45.5 months (p = 0.004), with a hazard ratio of 8.6, (95% C.I.: [2 – 37]). Using GTD_TOT with the best cut-off at 43 Gy, the same PFS values were obtained as after cycle 1 (p = 0.035). At multivariate analysis, a decrease in GTD_1 and, with lower impact, a higher global tumour volume were significantly associated with PFS < 24 months. We calculated the Tumour Control Probability of obtaining PFS > 24 months as a function of GTD_1. Discussion: Several statistical analyses seem to confirm that simple tumour dosimetry with 2 SPECT/CT scans after the first administration allows to predict PFS values after 4 × 7.4 GBq administrations of 177Lu[Lu]-DOTATATE in G1-G2 GEP NETs. This result qualitatively confirms recent findings by a Belgian and a French study. However, dosimetric thresholds are different. This probably comes from different cohort baseline characteristics, since the median PFS in our study (42 m) was longer than in the other studies (28 m and 31 m). Conclusion: Tumour dosimetry after the first administration of [177Lu]Lu-DOTATATE offers an important prognostic value in the clinical decision-making process, especially for the future as alternative emitters or administration schedule may become available. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

16. NETs of the Lung

Author

Prinzi, Natalie, Rossi, Roberta Elisa, Leuzzi, Giovanni, Pusceddu, Sara, Beretta, Giordano, editor, Berruti, Alfredo, editor, Bombardieri, Emilio, editor, Fazio, Nicola, editor, and Goletti, Orlando, editor

Published
2021
Full Text
View/download PDF

17. Emerging Treatment Options for Neuroendocrine Neoplasms of Unknown Primary Origin: Current Evidence and Future Perspectives

Author

Corti, Francesca, primary, Rossi, Roberta Elisa, additional, Cafaro, Pietro, additional, Passarella, Gaia, additional, Turla, Antonella, additional, Pusceddu, Sara, additional, Coppa, Jorgelina, additional, Oldani, Simone, additional, Guidi, Alessandro, additional, Longarini, Raffaella, additional, and Cortinovis, Diego Luigi, additional

Published
2024
Full Text
View/download PDF

18. Sequencing Treatments in Patients with Advanced Well-Differentiated Pancreatic Neuroendocrine Tumor (pNET): Results from a Large Multicenter Italian Cohort

Author

Panzuto, Francesco, primary, Andrini, Elisa, additional, Lamberti, Giuseppe, additional, Pusceddu, Sara, additional, Rinzivillo, Maria, additional, Gelsomino, Fabio, additional, Raimondi, Alessandra, additional, Bongiovanni, Alberto, additional, Davì, Maria Vittoria, additional, Cives, Mauro, additional, Brizzi, Maria Pia, additional, Persano, Irene, additional, Zatelli, Maria Chiara, additional, Puliafito, Ivana, additional, Tafuto, Salvatore, additional, and Campana, Davide, additional

Published
2024
Full Text
View/download PDF

19. Recent Advances in the Management of Typical and Atypical Lung Carcinoids

Author

Prinzi, Natalie, Rossi, Roberta Elisa, Proto, Claudia, Leuzzi, Giovanni, Raimondi, Alessandra, Torchio, Martina, Milione, Massimo, Corti, Francesca, Colombo, Elena, Prisciandaro, Michele, Cascella, Tommaso, Spreafico, Carlo, Beninato, Teresa, Coppa, Jorgelina, Lo Russo, Giuseppe, Di Bartolomeo, Maria, de Braud, Filippo, and Pusceddu, Sara

Published
2021
Full Text
View/download PDF

20. Pathological Characteristics, Management, and Prognosis of Rectal Neuroendocrine Tumors: A Retrospective Study from a Tertiary Hospital.

Author

Cavalcoli, Federica, Rausa, Emanuele, Ferrari, Davide, Rosa, Roberto, Maccauro, Marco, Pusceddu, Sara, Sabella, Giovanna, Cantù, Paolo, Vitellaro, Marco, Coppa, Jorgelina, and Mazzaferro, Vincenzo

Subjects
PROGRESSION-free survival, RECTUM tumors, OVERALL survival, NEUROENDOCRINE tumors, ENDOSCOPIC surgery
Abstract

Background: Rectal neuroendocrine tumors (rNENs) are rare, constituting 1–2% of rectal tumors, and are often asymptomatic, leading to challenges in early diagnosis. Current management guidelines recommend endoscopic resection for small lesions and surgical intervention for larger or high-risk tumors. This study aims to retrospectively analyze the pathological characteristics, management, and prognosis of rNEN patients. Methods: Data from the Neuroendocrine Tumor Registry at a tertiary hospital in Milan, Italy from 2005 to 2023 were retrospectively analyzed. Patient demographics, disease characteristics, pathology findings, treatment details, and surveillance data were collected. Statistical analyses included descriptive statistics, multivariable binary logistic regression, and Kaplan–Meier survival analysis. Results: Forty-five patients were included, 53.3% male with a mean age of 57.5 years. Most patients were asymptomatic, with incidental diagnosis during colonoscopy. Endoscopic excision was the primary treatment modality (77.8%), with surgical resection reserved for incomplete or inappropriate endoscopic resections. Disease progression occurred in 13 patients (28.9%), with tumor-related mortality of 22.2%. Kaplan–Meier analysis showed 5- and 10-year survival rates of 68.8% and 59.1%, respectively, with corresponding progression-free survival rates of 72.8% and 54.0%. Tumor stage was significantly associated with disease progression on multivariable analysis (OR = 7.230, p = 0.039). Conclusions: This study highlights the heterogeneous presentation and prognosis of rNENs, with a substantial proportion diagnosed incidentally. Endoscopic management was predominantly utilized, aligning with current guidelines for localized tumors. Tumor stage emerged as a significant predictor of disease progression, emphasizing the importance of accurate staging for optimal management. Further research is warranted to refine management protocols and validate these findings. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

21. NALIRIFOX, FOLFIRINOX, and Gemcitabine With Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Cancer

Author

Nichetti, Federico, primary, Rota, Simone, additional, Ambrosini, Paolo, additional, Pircher, Chiara, additional, Gusmaroli, Eleonora, additional, Droz Dit Busset, Michele, additional, Pusceddu, Sara, additional, Sposito, Carlo, additional, Coppa, Jorgelina, additional, Morano, Federica, additional, Pietrantonio, Filippo, additional, Di Bartolomeo, Maria, additional, Mariani, Luigi, additional, Mazzaferro, Vincenzo, additional, de Braud, Filippo, additional, and Niger, Monica, additional

Published
2024
Full Text
View/download PDF

26. Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues

Author

Pusceddu, Sara, Vernieri, Claudio, Di Maio, Massimo, Marconcini, Riccardo, Spada, Francesca, Massironi, Sara, Ibrahim, Toni, Brizzi, Maria Pia, Campana, Davide, Faggiano, Antongiulio, Giuffrida, Dario, Rinzivillo, Maria, Cingarlini, Sara, Aroldi, Francesca, Antonuzzo, Lorenzo, Berardi, Rossana, Catena, Laura, De Divitiis, Chiara, Ermacora, Paola, Perfetti, Vittorio, Fontana, Annalisa, Razzore, Paola, Carnaghi, Carlo, Davì, Maria Vittoria, Cauchi, Carolina, Duro, Marilina, Ricci, Sergio, Fazio, Nicola, Cavalcoli, Federica, Bongiovanni, Alberto, La Salvia, Anna, Brighi, Nicole, Colao, Annamaria, Puliafito, Ivana, Panzuto, Francesco, Ortolani, Silvia, Zaniboni, Alberto, Di Costanzo, Francesco, Torniai, Mariangela, Bajetta, Emilio, Tafuto, Salvatore, Garattini, Silvio Ken, Femia, Daniela, Prinzi, Natalie, Concas, Laura, Lo Russo, Giuseppe, Milione, Massimo, Giacomelli, Luca, Buzzoni, Roberto, Delle Fave, Gianfranco, Mazzaferro, Vincenzo, and de Braud, Filippo

Published
2018
Full Text
View/download PDF

28. Sunitinib in patients with pre-treated pancreatic neuroendocrine tumors: A real-world study

Author

Rinzivillo, Maria, Fazio, Nicola, Pusceddu, Sara, Spallanzani, Andrea, Ibrahim, Toni, Campana, Davide, Marconcini, Riccardo, Partelli, Stefano, Badalamenti, Giuseppe, Brizzi, Maria Pia, Catena, Laura, Schinzari, Giovanni, Carnaghi, Carlo, Berardi, Rossana, Faggiano, Antongiulio, Antonuzzo, Lorenzo, Spada, Francesca, Gritti, Sara, Femia, Daniela, Gelsomino, Fabio, Bongiovanni, Alberto, Ricci, Sergio, Brighi, Nicole, Falconi, Massimo, Delle Fave, Gianfranco, and Panzuto, Francesco

Published
2018
Full Text
View/download PDF

33. Proposal of early CT morphological criteria for response of liver metastases to systemic treatments in gastroenteropancreatic neuroendocrine tumors: Alternatives to RECIST

Author

de Mestier, Louis, primary, Resche‐Rigon, Matthieu, additional, Dromain, Clarisse, additional, Lamarca, Angela, additional, La Salvia, Anna, additional, de Baker, Lesley, additional, Fehrenbach, Uli, additional, Pusceddu, Sara, additional, Colao, Annamaria, additional, Borbath, Ivan, additional, de Haas, Robbert, additional, Rinzivillo, Maria, additional, Zerbi, Alessandro, additional, Funicelli, Luigi, additional, de Herder, Wouter W., additional, Selberherr, Andreas, additional, Wagner, Anna Dorothea, additional, Manoharan, Prakash, additional, De Cima, Andrea, additional, Lybaert, Willem, additional, Jann, Henning, additional, Prinzi, Natalie, additional, Faggiano, Antongiulio, additional, Annet, Laurence, additional, Walenkamp, Annemiek, additional, Panzuto, Francesco, additional, Pedicini, Vittorio, additional, Pitoni, Maria Giovanna, additional, Siebenhuener, Alexander, additional, Mayerhoefer, Marius E., additional, Ruszniewski, Philippe, additional, and Vullierme, Marie‐Pierre, additional

Published
2023
Full Text
View/download PDF

34. Gender related differences in patients with carcinoid syndrome: new insights from a multicenter retrospective study

Author

Grazia, Tarsitano Maria, primary, Altieri, Barbara, additional, Grossrubatscher, Erika, additional, Minotta, Roberto, additional, Zamponi, Virginia, additional, Albertelli, Manuela, additional, Appetecchia, Marialuisa, additional, Pia, Brizzi Maria, additional, Vittoria, Davi Maria, additional, Fanciulli, Giuseppe, additional, Giannetta, Elisa, additional, Guarnotta, Valentina, additional, La, Salvia Anna, additional, Lania, Andrea, additional, Lavezzi, Elisabetta, additional, Malandrino, Pasqualino, additional, Mazzilli, Rossella, additional, Modica, Roberta, additional, Pia, Anna, additional, Prinzi, Natalie, additional, Pusceddu, Sara, additional, Razzore, Paula, additional, Zanata, Isabella, additional, Chiara, Zatelli Maria, additional, Isidori, Andrea, additional, Maria, Colao Anna, additional, Faggiano, Antongiulio, additional, and Maddalena, Ruggeri Rosaria, additional

Published
2023
Full Text
View/download PDF

35. Targeted Genomic Profiling and Chemotherapy Outcomes in Grade 3 Gastro-Entero-Pancreatic Neuroendocrine Tumors (G3 GEP-NET)

Author

Lamberti, Giuseppe, primary, Prinzi, Natalie, additional, Bongiovanni, Alberto, additional, Torniai, Mariangela, additional, Andrini, Elisa, additional, de Biase, Dario, additional, Malvi, Deborah, additional, Mosca, Mirta, additional, Berardi, Rossana, additional, Ibrahim, Toni, additional, Pusceddu, Sara, additional, and Campana, Davide, additional

Published
2023
Full Text
View/download PDF

36. COVID-19 in patients with neuroendocrine neoplasms: two-year results of the INTENSIVE study

Author

Fazio, N, Gervaso, L, Halfdanarson, T, Sonbol, M, Eiring, R, Pusceddu, S, Prinzi, N, Lombardi Stocchetti, B, Grozinsky-Glasberg, S, Gross, D, Walter, T, Robelin, P, Lombard-Bohas, C, Frassoni, S, Bagnardi, V, Antonuzzo, L, Sparano, C, Massironi, S, Gelsomino, F, Bongiovanni, A, Ranallo, N, Tafuto, S, Rossi, M, Cives, M, Rasul, K, Hamid, H, Chirco, A, Squadroni, M, La Salvia, A, Hernando, J, Hofland, J, Koumarianou, A, Boselli, S, Tamayo, D, Mazzon, C, Rubino, M, Spada, F, Fazio, Nicola, Gervaso, Lorenzo, Halfdanarson, Thorvardur R, Sonbol, Mohamad, Eiring, Rachel A, Pusceddu, Sara, Prinzi, Natalie, Lombardi Stocchetti, Benedetta, Grozinsky-Glasberg, Simona, Gross, David J, Walter, Thomas, Robelin, Patrick, Lombard-Bohas, Catherine, Frassoni, Samuele, Bagnardi, Vincenzo, Antonuzzo, Lorenzo, Sparano, Clotilde, Massironi, Sara, Gelsomino, Fabio, Bongiovanni, Alberto, Ranallo, Nicoletta, Tafuto, Salvatore, Rossi, Maura, Cives, Mauro, Rasul, Kakil Ibrahim, Hamid, Hytham, Chirco, Alessandra, Squadroni, Michela, La Salvia, Anna, Hernando, Jorge, Hofland, Johannes, Koumarianou, Anna, Boselli, Sabrina, Tamayo, Darina, Mazzon, Cristina, Rubino, Manila, Spada, Francesca, Fazio, N, Gervaso, L, Halfdanarson, T, Sonbol, M, Eiring, R, Pusceddu, S, Prinzi, N, Lombardi Stocchetti, B, Grozinsky-Glasberg, S, Gross, D, Walter, T, Robelin, P, Lombard-Bohas, C, Frassoni, S, Bagnardi, V, Antonuzzo, L, Sparano, C, Massironi, S, Gelsomino, F, Bongiovanni, A, Ranallo, N, Tafuto, S, Rossi, M, Cives, M, Rasul, K, Hamid, H, Chirco, A, Squadroni, M, La Salvia, A, Hernando, J, Hofland, J, Koumarianou, A, Boselli, S, Tamayo, D, Mazzon, C, Rubino, M, Spada, F, Fazio, Nicola, Gervaso, Lorenzo, Halfdanarson, Thorvardur R, Sonbol, Mohamad, Eiring, Rachel A, Pusceddu, Sara, Prinzi, Natalie, Lombardi Stocchetti, Benedetta, Grozinsky-Glasberg, Simona, Gross, David J, Walter, Thomas, Robelin, Patrick, Lombard-Bohas, Catherine, Frassoni, Samuele, Bagnardi, Vincenzo, Antonuzzo, Lorenzo, Sparano, Clotilde, Massironi, Sara, Gelsomino, Fabio, Bongiovanni, Alberto, Ranallo, Nicoletta, Tafuto, Salvatore, Rossi, Maura, Cives, Mauro, Rasul, Kakil Ibrahim, Hamid, Hytham, Chirco, Alessandra, Squadroni, Michela, La Salvia, Anna, Hernando, Jorge, Hofland, Johannes, Koumarianou, Anna, Boselli, Sabrina, Tamayo, Darina, Mazzon, Cristina, Rubino, Manila, and Spada, Francesca

Abstract

We conducted a retrospective/prospective worldwide study on patients with neuroendocrine neoplasms (NENs) and a molecularly proven SARS-CoV-2 positivity. Preliminary results regarding 85 patients of the INTENSIVE study have been published in 2021. Now we are reporting the 2-year analysis. Here, we are reporting data from consecutive patients enrolled between 1 June 2020, and 31 May 2022. Among the 118 contacted centers, 25 were active to enroll and 19 actively recruiting at the time of data cut-off for a total of 280 patients enrolled. SARS-CoV-2 positivity occurred in 47.5% of patients in 2020, 35.1% in 2021, and 17.4% in 2022. The median age for COVID-19 diagnosis was 60 years. Well-differentiated tumors, non-functioning, metastatic stage, and gastroenteropancreatic (GEP) primary sites represented most of the NENs. COVID-19-related pneumonia occurred in 22.8% of the total, with 61.3% of them requiring hospitalization; 11 patients (3.9%) needed sub-intensive or intensive care unit therapies and 14 patients died (5%), in 11 cases (3.9%) directly related to COVID-19. Diabetes mellitus and age at COVID-19 diagnosis > 70 years were significantly associated with COVID-19 mortality, whereas thoracic primary site with COVID-19 morbidity. A significant decrease in both hospitalization and pneumonia occurred in 2022 vs 2020. In our largest series of NEN patients with COVID-19, the NEN population is similar to the general population of patients with NEN regardless of COVID-19. However, older age, non-GEP primary sites and diabetes mellitus should be carefully considered for increased COVID-19 morbidity and mortality. Relevant information could be derived by integrating our results with NENs patients included in other cancer patients with COVID-19 registries.

Published
2023

37. Proposal of early CT morphological criteria for response of liver metastases to systemic treatments in gastroenteropancreatic neuroendocrine tumors:Alternatives to RECIST

Author

de Mestier, Louis, Resche-Rigon, Matthieu, Dromain, Clarisse, Lamarca, Angela, La Salvia, Anna, de Baker, Lesley, Fehrenbach, Uli, Pusceddu, Sara, Colao, Annamaria, Borbath, Ivan, de Haas, Robbert, Rinzivillo, Maria, Zerbi, Alessandro, Funicelli, Luigi, de Herder, Wouter W., Selberherr, Andreas, Wagner, Anna Dorothea, Manoharan, Prakash, De Cima, Andrea, Lybaert, Willem, Jann, Henning, Prinzi, Natalie, Faggiano, Antongiulio, Annet, Laurence, Walenkamp, Annemiek, Panzuto, Francesco, Pedicini, Vittorio, Pitoni, Maria Giovanna, Siebenhuener, Alexander, Mayerhoefer, Marius E., Ruszniewski, Philippe, Vullierme, Marie Pierre, de Mestier, Louis, Resche-Rigon, Matthieu, Dromain, Clarisse, Lamarca, Angela, La Salvia, Anna, de Baker, Lesley, Fehrenbach, Uli, Pusceddu, Sara, Colao, Annamaria, Borbath, Ivan, de Haas, Robbert, Rinzivillo, Maria, Zerbi, Alessandro, Funicelli, Luigi, de Herder, Wouter W., Selberherr, Andreas, Wagner, Anna Dorothea, Manoharan, Prakash, De Cima, Andrea, Lybaert, Willem, Jann, Henning, Prinzi, Natalie, Faggiano, Antongiulio, Annet, Laurence, Walenkamp, Annemiek, Panzuto, Francesco, Pedicini, Vittorio, Pitoni, Maria Giovanna, Siebenhuener, Alexander, Mayerhoefer, Marius E., Ruszniewski, Philippe, and Vullierme, Marie Pierre

Abstract

RECIST 1.1 criteria are commonly used with computed tomography (CT) to evaluate the efficacy of systemic treatments in patients with neuroendocrine tumors (NETs) and liver metastases (LMs), but their relevance is questioned in this setting. We aimed to explore alternative criteria using different numbers of measured LMs and thresholds of size and density variation. We retrospectively studied patients with advanced pancreatic or small intestine NETs with LMs, treated with systemic treatment in the first-and/or second-line, without early progression, in 14 European expert centers. We compared time to treatment failure (TTF) between responders and non-responders according to various criteria defined by 0%, 10%, 20% or 30% decrease in the sum of LM size, and/or by 10%, 15% or 20% decrease in LM density, measured on two, three or five LMs, on baseline (≤1 month before treatment initiation) and first revaluation (≤6 months) contrast-enhanced CT scans. Multivariable Cox proportional hazard models were performed to adjust the association between response criteria and TTF on prognostic factors. We included 129 systemic treatments (long-acting somatostatin analogs 41.9%, chemotherapy 26.4%, targeted therapies 31.8%), administered as first-line (53.5%) or second-line therapies (46.5%) in 91 patients. A decrease ≥10% in the size of three LMs was the response criterion that best predicted prolonged TTF, with significance at multivariable analysis (HR 1.90; 95% CI: 1.06–3.40; p =.03). Conversely, response defined by RECIST 1.1 did not predict prolonged TTF (p =.91), and neither did criteria based on changes in LM density. A ≥10% decrease in size of three LMs could be a more clinically relevant criterion than the current 30% threshold utilized by RECIST 1.1 for the evaluation of treatment efficacy in patients with advanced NETs. Its implementation in clinical trials is mandatory for prospective validation. Criteria based on changes in LM density were not predictive of treatment

Published
2023

39. COVID-19 in patients with neuroendocrine neoplasms: two-year results of the INTENSIVE study

Author

Fazio, Nicola, primary, Gervaso, Lorenzo, additional, Halfdanarson, Thorvardur R, additional, Sonbol, Mohamad, additional, Eiring, Rachel A, additional, Pusceddu, Sara, additional, Prinzi, Natalie, additional, Lombardi Stocchetti, Benedetta, additional, Grozinsky-Glasberg, Simona, additional, Gross, David J., additional, Walter, Thomas, additional, Robelin, Patrick, additional, Lombard-Bohas, Catherine, additional, Frassoni, Samuele, additional, Bagnardi, Vincenzo, additional, Antonuzzo, Lorenzo, additional, Sparano, Clotilde, additional, Massironi, Sara, additional, Gelsomino, Fabio, additional, Bongiovanni, Alberto, additional, Ranallo, Nicoletta, additional, Tafuto, Salvatore, additional, Rossi, Maura, additional, Cives, Mauro, additional, Rasul, Kakil Ibrahim, additional, Hamid, Hytham, additional, Chirco, Alessandra, additional, Squadroni, Michela, additional, La Salvia, Anna, additional, Hernando, Jorge, additional, Hofland, Johannes, additional, Koumarianou, Anna, additional, Boselli, Sabrina, additional, Tamayo, Darina, additional, Mazzon, Cristina, additional, Rubino, Manila, additional, and Spada, Francesca, additional

Published
2023
Full Text
View/download PDF

40. Ascl1 and OTP tumour expressions are associated with disease‐free survival in lung atypical carcinoids

Author

Centonze, Giovanni, primary, Maisonneuve, Patrick, additional, Simbolo, Michele, additional, Lagano, Vincenzo, additional, Grillo, Federica, additional, Prinzi, Natalie, additional, Pusceddu, Sara, additional, Missiato, Loretta, additional, Colantuono, Marilena, additional, Sabella, Giovanna, additional, Bercich, Luisa, additional, Mangogna, Alessandro, additional, Rolli, Luigi, additional, Grisanti, Salvatore, additional, Benvenuti, Mauro Roberto, additional, Pastorino, Ugo, additional, Roz, Luca, additional, Scarpa, Aldo, additional, Berruti, Alfredo, additional, Capella, Carlo, additional, and Milione, Massimo, additional

Published
2023
Full Text
View/download PDF

41. COVID-19 in patients with neuroendocrine neoplasms: two-year results of the INTENSIVE study

Author

Fazio, Nicola, Gervaso, Lorenzo, Halfdanarson, Thorvardur R, Sonbol, Mohamad, Eiring, Rachel A, Pusceddu, Sara, Prinzi, Natalie, Lombardi Stocchetti, Benedetta, Grozinsky-Glasberg, Simona, Gross, David J, Walter, Thomas, Robelin, Patrick, Lombard-Bohas, Catherine, Frassoni, Samuele, Bagnardi, Vincenzo, Antonuzzo, Lorenzo, Sparano, Clotilde, Massironi, Sara, Gelsomino, Fabio, Bongiovanni, Alberto, Ranallo, Nicoletta, Tafuto, Salvatore, Rossi, Maura, Cives, Mauro, Rasul, Kakil Ibrahim, Hamid, Hytham, Chirco, Alessandra, Squadroni, Michela, La Salvia, Anna, Hernando, Jorge, Hofland, Johannes, Koumarianou, Anna, Boselli, Sabrina, Tamayo, Darina, Mazzon, Cristina, Rubino, Manila, Spada, Francesca, Fazio, N, Gervaso, L, Halfdanarson, T, Sonbol, M, Eiring, R, Pusceddu, S, Prinzi, N, Lombardi Stocchetti, B, Grozinsky-Glasberg, S, Gross, D, Walter, T, Robelin, P, Lombard-Bohas, C, Frassoni, S, Bagnardi, V, Antonuzzo, L, Sparano, C, Massironi, S, Gelsomino, F, Bongiovanni, A, Ranallo, N, Tafuto, S, Rossi, M, Cives, M, Rasul, K, Hamid, H, Chirco, A, Squadroni, M, La Salvia, A, Hernando, J, Hofland, J, Koumarianou, A, Boselli, S, Tamayo, D, Mazzon, C, Rubino, M, and Spada, F

Subjects
COVID 19, neuroendocrine neoplasms
Abstract

Preliminary results regarding 85 patients of the INTENSIVE study have been published in 2021. Now we are reporting the 2-year analysis. We conducted a retrospective/prospective worldwide study on patients with neuroendocrine neoplasms (NENs) and a molecularly proven SARS-CoV-2 positivity. Here we are reporting data from consecutive patients enrolled between June 01, 2020, and May 31, 2022. Among the 118 contacted centers, 25 were active to enroll and 19 actively recruiting at the time of data cut-off for a total of 280 patients enrolled. SARS-CoV-2 positivity occurred in 47.5% of patients in 2020, 35.1% in 2021 and 17.4% in 2022. Median age at COVID-19 diagnosis was 60 years. Well differentiated tumors, non-functioning, metastatic stage and gastroenteropancreatic (GEP) primary site represented most of NENs. COVID-19-related pneumonia occurred in 22.8% of the total, with 61.3% of them requiring hospitalization; 11 patients (3.9%) needed sub-intensive or intensive care unit therapies and 14 patients died (5%), in 11 cases (3.9%) directly related to COVID-19. Thoracic and other NEN primary site were associated with hospitalization for COVID-19 and with sub-intensive or intensive care. A significant decrease in both hospitalization and pneumonia occurred in 2022 versus 2020. In our largest series of NEN patients with COVID-19, the NEN population is similar to the general population regardless of COVID-19. However, older age, non-GEP primary sites and diabetes mellitus should be carefully considered for increased COVID-19 morbidity and mortality. Relevant information could be derived by integrating our results with NENs patients included in other cancer patients and COVID-19 registries.

Published
2023

42. Everolimus as first line therapy for pancreatic neuroendocrine tumours: current knowledge and future perspectives

Author

Gallo, Marco, Malandrino, Pasqualino, Fanciulli, Giuseppe, Rota, Francesca, Faggiano, Antongiulio, Colao, Annamaria, Colao, Annamaria, Albertelli, Manuela, Amoroso, Vito, Arvat, Emanuela, Badalamenti, Giuseppe, Bajetta, Emilio, Baldelli, Roberto, Bianchi, Antonio, Botti, Gerardo, Buzzoni, Roberto, Campana, Davide, Carnaghi, Carlo, Cartenì, Giacomo, Cingarlini, Sara, Circelli, Luisa, Colantuoni, Vittorio, Coppa, Jorgelina, Corcione, Francesco, Davı´, Maria Vittoria, De Rosa, Gaetano, Degli Uberti, Ettore, Del Basso De Caro, Marialaura, Di Sarno, Antonella, Falconi, Massimo, Ferolla, Piero, Ferone, Diego, Fiore, Francesco, Gaudenzi, Germano, Giordano, Carla, Giuffrida, Dario, Grossrubatscher, Erika Maria, Guadagno, Elia, Guarnotta, Valentina, Izzo, Francesco, Lania, Andrea, Lastoria, Secondo, Leo, Silvana, Lo Calzo, Fabio, Logoluso, Francesco, Manzoni, Marco, Marchetti, Massimo, Martini, Chiara, Messina, Erika, Milione, Massimo, Modica, Roberta, Montesarchio, Vincenzo, Muto, Pietro, Nappi, Oscar, Nazzari, Elena, Panzuto, Francesco, Pia, Anna, Piovesan, Alessandro, Pizza, Genoveffa, Pontecorvi, Alfredo, Pusceddu, Sara, Razzore, Paola, Riccardi, Ferdinando, Rindi, Guido, Sciammarella, Concetta, Spada, Francesca, Tafuto, Salvatore, Versari, Annibale, Vitale, Giovanni, Zatelli, Maria Chiara, and On behalf of NIKE Group

Published
2017
Full Text
View/download PDF

43. Prognostic Factors Across Poorly Differentiated Neuroendocrine Neoplasms: a Pooled Analysis

Author

Centonze, Giovanni, primary, Maisonneuve, Patrick, additional, Prinzi, Natalie, additional, Pusceddu, Sara, additional, Albarello, Luca, additional, Pisa, Eleonora, additional, Barberis, Massimo, additional, Vanoli, Alessandro, additional, Spaggiari, Paola, additional, Bossi, Paola, additional, Cattaneo, Laura, additional, Sabella, Giovanna, additional, Solcia, Enrico, additional, La Rosa, Stefano, additional, Grillo, Federica, additional, Tagliabue, Giovanna, additional, Scarpa, Aldo, additional, Papotti, Mauro, additional, Volante, Marco, additional, Mangogna, Alessandro, additional, Del Gobbo, Alessandro, additional, Ferrero, Stefano, additional, Rolli, Luigi, additional, Roca, Elisa, additional, Bercich, Luisa, additional, Benvenuti, Mauro, additional, Messerini, Luca, additional, Inzani, Frediano, additional, Pruneri, Giancarlo, additional, Busico, Adele, additional, Perrone, Federica, additional, Tamborini, Elena, additional, Pellegrinelli, Alessio, additional, Kankava, Ketevani, additional, Berruti, Alfredo, additional, Pastorino, Ugo, additional, Fazio, Nicola, additional, Sessa, Fausto, additional, Capella, Carlo, additional, Rindi, Guido, additional, and Milione, Massimo, additional

Published
2022
Full Text
View/download PDF

44. Lung carcinoid tumours: histology and Ki‐67, the eternal rivalry

Author

Centonze, Giovanni, primary, Maisonneuve, Patrick, additional, Simbolo, Michele, additional, Lagano, Vincenzo, additional, Grillo, Federica, additional, Fabbri, Alessandra, additional, Prinzi, Natalie, additional, Garzone, Giovanna, additional, Filugelli, Martina, additional, Pardo, Carlotta, additional, Mietta, Alessia, additional, Pusceddu, Sara, additional, Sabella, Giovanna, additional, Bercich, Luisa, additional, Mangogna, Alessandro, additional, Rolli, Luigi, additional, Grisanti, Salvatore, additional, Benvenuti, Mauro Roberto, additional, Pastorino, Ugo, additional, Roz, Luca, additional, Scarpa, Aldo, additional, Berruti, Alfredo, additional, Capella, Carlo, additional, and Milione, Massimo, additional

Published
2022
Full Text
View/download PDF

45. Combined Large Cell Neuroendocrine Carcinomas of the Lung: Integrative Molecular Analysis Identifies Subtypes with Potential Therapeutic Implications

Author

Simbolo, Michele, primary, Centonze, Giovanni, additional, Giudice, Luca, additional, Grillo, Federica, additional, Maisonneuve, Patrick, additional, Gkountakos, Anastasios, additional, Ciaparrone, Chiara, additional, Cattaneo, Laura, additional, Sabella, Giovanna, additional, Giugno, Rosalba, additional, Bossi, Paola, additional, Spaggiari, Paola, additional, Del Gobbo, Alessandro, additional, Ferrero, Stefano, additional, Mastracci, Luca, additional, Fabbri, Alessandra, additional, Filugelli, Martina, additional, Garzone, Giovanna, additional, Prinzi, Natalie, additional, Pusceddu, Sara, additional, Testi, Adele, additional, Monti, Valentina, additional, Rolli, Luigi, additional, Mangogna, Alessandro, additional, Bercich, Luisa, additional, Benvenuti, Mauro Roberto, additional, Bria, Emilio, additional, Pilotto, Sara, additional, Berruti, Alfredo, additional, Pastorino, Ugo, additional, Capella, Carlo, additional, Infante, Maurizio, additional, Milella, Michele, additional, Scarpa, Aldo, additional, and Milione, Massimo, additional

Published
2022
Full Text
View/download PDF

46. COVID-19 in patients with neuroendocrine neoplasms: 2-year results of the INTENSIVE study.

Author

Fazio, Nicola, Gervaso, Lorenzo, Halfdanarson, Thorvardur R., Sonbol, Mohamad, Eiring, Rachel A., Pusceddu, Sara, Prinzi, Natalie, Stocchetti, Benedetta Lombardi, Grozinsky-Glasberg, Simona, Gross, David J., Walter, Thomas, Robelin, Patrick, Lombard-Bohas, Catherine, Frassoni, Samuele, Bagnardi, Vincenzo, Antonuzzo, Lorenzo, Sparano, Clotilde, Massironi, Sara, Gelsomino, Fabio, and Bongiovanni, Alberto

Subjects
NEUROENDOCRINE tumors, COVID-19, INTENSIVE care units, MEDICAL registries, COVID-19 testing
Abstract

We conducted a retrospective/prospective worldwide study on patients with neuroendocrine neoplasms (NENs) and a molecularly proven SARS-CoV-2 positivity. Preliminary results regarding 85 patients of the INTENSIVE study have been published in 2021. Now we are reporting the 2-year analysis. Here, we are reporting data from consecutive patients enrolled between 1 June 2020, and 31 May 2022. Among the 118 contacted centers, 25 were active to enroll and 19 actively recruiting at the time of data cut-off for a total of 280 patients enrolled. SARS-CoV-2 positivity occurred in 47.5% of patients in 2020, 35.1% in 2021, and 17.4% in 2022. The median age for COVID-19 diagnosis was 60 years. Well-differentiated tumors, non-functioning, metastatic stage, and gastroenteropancreatic (GEP) primary sites represented most of the NENs. COVID-19-related pneumonia occurred in 22.8% of the total, with 61.3% of them requiring hospitalization; 11 patients (3.9%) needed sub-intensive or intensive care unit therapies and 14 patients died (5%), in 11 cases (3.9%) directly related to COVID-19. Diabetes mellitus and age at COVID-19 diagnosis > 70 years were significantly associated with COVID-19 mortality, whereas thoracic primary site with COVID-19 morbidity. A significant decrease in both hospitalization and pneumonia occurred in 2022 vs 2020. In our largest series of NEN patients with COVID-19, the NEN population is similar to the general population of patients with NEN regardless of COVID-19. However, older age, non-GEP primary sites and diabetes mellitus should be carefully considered for increased COVID-19 morbidity and mortality. Relevant information could be derived by integrating our results with NENs patients included in other cancer patients with COVID-19 registries. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

47. Prognostic Factors across Poorly Differentiated Neuroendocrine Neoplasms: A Pooled Analysis.

Author

Centonze, Giovanni, Maisonneuve, Patrick, Prinzi, Natalie, Pusceddu, Sara, Albarello, Luca, Pisa, Eleonora, Barberis, Massimo, Vanoli, Alessandro, Spaggiari, Paola, Bossi, Paola, Cattaneo, Laura, Sabella, Giovanna, Solcia, Enrico, La Rosa, Stefano, Grillo, Federica, Tagliabue, Giovanna, Scarpa, Aldo, Papotti, Mauro, Volante, Marco, and Mangogna, Alessandro

Subjects
NEUROENDOCRINE tumors, PROGNOSIS, PROPORTIONAL hazards models, GASTROPARESIS
Abstract

Introduction: Poorly differentiated neuroendocrine carcinomas (NECs) are characterized by aggressive clinical course and poor prognosis. No reliable prognostic markers have been validated to date; thus, the definition of a specific NEC prognostic algorithm represents a clinical need. This study aimed to analyze a large NEC case series to validate the specific prognostic factors identified in previous studies on gastro-entero-pancreatic and lung NECs and to assess if further prognostic parameters can be isolated. Methods: A pooled analysis of four NEC retrospective studies was performed to evaluate the prognostic role of Ki-67 cut-off, the overall survival (OS) according to primary cancer site, and further prognostic parameters using multivariable Cox proportional hazards model and machine learning random survival forest (RSF). Results: 422 NECs were analyzed. The most represented tumor site was the colorectum (n = 156, 37%), followed by the lungs (n = 111, 26%), gastroesophageal site (n = 83, 20%; 66 gastric, 79%) and pancreas (n = 42, 10%). The Ki-67 index was the most relevant predictor, followed by morphology (pure or mixed/combined NECs), stage, and site. The predicted RSF response for survival at 1, 2, or 3 years showed decreasing survival with increasing Ki-67, pure NEC morphology, stage III–IV, and colorectal NEC disease. Patients with Ki-67 <55% and mixed/combined morphology had better survival than those with pure morphology. Morphology pure or mixed/combined became irrelevant in NEC survival when Ki-67 was ≥55%. The prognosis of metastatic patients who did not receive any treatment tended to be worse compared to that of the treated group. The prognostic impact of Rb1 immunolabeling appears to be limited when multiple risk factors are simultaneously assessed. Conclusion: The most effective parameters to predict OS for NEC patients could be Ki-67, pure or mixed/combined morphology, stage, and site. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

48. MGMT inactivation as a new biomarker in patients with advanced biliary tract cancers

Author

Niger, Monica, primary, Nichetti, Federico, additional, Casadei‐Gardini, Andrea, additional, Morano, Federica, additional, Pircher, Chiara, additional, Tamborini, Elena, additional, Perrone, Federica, additional, Canale, Matteo, additional, Lipka, Daniel B., additional, Vingiani, Andrea, additional, Agnelli, Luca, additional, Dobberkau, Anna, additional, Hüllein, Jennifer, additional, Korell, Felix, additional, Heilig, Christoph E., additional, Pusceddu, Sara, additional, Corti, Francesca, additional, Droz, Michele, additional, Ulivi, Paola, additional, Prisciandaro, Michele, additional, Antista, Maria, additional, Bini, Marta, additional, Cattaneo, Laura, additional, Milione, Massimo, additional, Glimm, Hanno, additional, Köhler, Bruno C., additional, Pruneri, Giancarlo, additional, Hübschmann, Daniel, additional, Fröhling, Stefan, additional, Mazzaferro, Vincenzo, additional, Pietrantonio, Filippo, additional, Di Bartolomeo, Maria, additional, and de Braud, Filippo, additional

Published
2022
Full Text
View/download PDF

49. Metastatic pheochromocytomas and paragangliomas: where are we?

Author

Prinzi, Natalie, primary, Corti, Francesca, additional, Torchio, Martina, additional, Niger, Monica, additional, Antista, Maria, additional, Pagani, Filippo, additional, Beninato, Teresa, additional, Pulice, Iolanda, additional, Rossi, Roberta Elisa, additional, Coppa, Jorgelina, additional, Cascella, Tommaso, additional, Giacomelli, Luca, additional, Di Bartolomeo, Maria, additional, Milione, Massimo, additional, de Braud, Filippo, additional, and Pusceddu, Sara, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results